DiscoveRx Provides PathHunter™ Technology to NIH
News Nov 04, 2005
DiscoveRx has announced that it has signed an agreement with the National Institutes of Health which will provide initial access to their PathHunter technology for small molecule screening against selected targets of interest to the Molecular Libraries Roadmap Initiative.
PathHunter is a cell-based assay technology ideally suited to high throughput screening that monitors cell signaling pathways.
The movement of proteins is monitored in a homogenous assay format within the cell using positional complementation.
This approach has been applied to a range of target molecules of interest to drug discovery, including kinases, transcription factors, phosphatases and nuclear hormone receptors, and offers a convenient, non-imaging assay format that is amenable to high throughput automation systems.
“We are very pleased to be working with the NIH Chemical Genomics Center to help accelerate their screening efforts,” stated Dr. Richard Eglen, CSO of DiscoveRx.
“We believe that our technology addresses many of the key benefits of more complex cell-based assays that employ imaging, but in a format specifically optimized for higher throughput screening campaigns.”
“Our EFC technology is a proven in vitro biochemical screening method, and the PathHunter products now apply this technology in a novel, whole-cell assay.”
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018